Is Lugol chromoendoscopy omissible in screening for esophageal squamous cell carcinoma?
Digestive Endoscopy · 2024
DOI: 10.1111/den.14873 ↗At a glance
Editorial in Digestive Endoscopy, 2024. Written by Tomohiro Kadota and 1 co-authors. Institution: Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Chiba, Japan. Major MEDLINE topics: Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Coloring Agents, Iodides. 10 references.
Abstract (original language)
The development of multiple metachronous cancers in the remaining esophagus after treatment of esophageal squamous cell carcinoma (ESCC) is a long-term management problem.The annual incidence of multiple metachronous cancers, especially after endoscopic resection, is approximately 10% per year. 1 In particular, the grade according to the number of Lugol-voiding lesions (LVLs) per endoscopic view has been reported to stratify the risk. 1
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Chiba, Japan.
ORCID profiles: Tomohiro Kadota, Tomonori Yano
Cite
APA
Kadota, T., & Yano, T. (2024). Is Lugol chromoendoscopy omissible in screening for esophageal squamous cell carcinoma?. Digestive Endoscopy. https://doi.org/10.1111/den.14873
Vancouver
Kadota T, Yano T. Is Lugol chromoendoscopy omissible in screening for esophageal squamous cell carcinoma?. Digestive Endoscopy. 2024. doi:10.1111/den.14873
BibTeX
@article{Kadota2024,
author = {Kadota, Tomohiro and Yano, Tomonori},
title = {Is Lugol chromoendoscopy omissible in screening for esophageal squamous cell carcinoma?},
journal = {Digestive Endoscopy},
year = {2024},
doi = {10.1111/den.14873}
}
EUVIMED